EXHIBIT 10.7
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
FOR THE PORTIONS MARKED [***]
AGREEMENT BY AND BETWEEN
ARENA PHARMACEUTICALS, INC.
AND
TAISHO PHARMACEUTICAL CO., LTD.
TABLE OF CONTENTS
PAGE
Article I. Definitions 1
Article II. GPCR Selection By Taisho; Technology Access Fee 5
Article III. Arena Activities 6
Article IV. Research and Development Fees 7
Article V. License Grant 8
Article VI. Screening By Arena 9
Article VII. Clinical Development of CART-TM- Identified Compound 10
Article VIII. Marketing Authorization 12
Article IX. Clinical Development of Subsequent Compounds 13
Article X. Royalty Payments 15
Article XI. Payment Arrangement 16
Article XII. Confidentiality 16
Article XIII. Patent Infringement And Enforcement 17
Article XIV. Representations And Warranties 18
Article XV. Indemnity 18
Article XVI. Termination 19
Article XVII. Relationship of the Parties 20
Article XVIII. Miscellaneous Provisions 20
Signature Blocks 23
--PLEASE NOTE--
Provisions Within This Agreement Are Deemed "CONFIDENTIAL" In Accordance
With The Terms of Article XII.
Reviewers are advised to confirm with their attorney
as to any obligations and/or requirements regarding
review of this Agreement
AGREEMENT
This Agreement ("Agreement") is effective as of May 29, 2000
("Effective Date") by and between ARENA PHARMACEUTICALS, INC., having a place of
business at 0000 Xxxxx Xxxxx Xxxxx, Xxx Xxxxx, Xxxxxxxxxx, 00000 XXX ("Arena"),
and TAISHO PHARMACEUTICAL CO., LTD., having a place of business at 00-0, Xxxxxx
0-Xxxxx, Xxxxxxxxx, Xxxxx 000-0000, XXXXX ("Taisho").
WHEREAS, Taisho is a pharmaceutical company focused on contributing to
the maintenance and improvement of consumer's health by creating and providing
quality drugs, related healthcare products and information services that satisfy
consumers with various lifestyles;
WHEREAS, Arena is a biopharmaceutical organization focused on the
discovery and development of innovative therapeutics;
WHEREAS, Arena and Taisho each desire to enter into this Agreement on
the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, Arena and Taisho hereby agree as follows:
ARTICLE I
DEFINITIONS
Unless otherwise specifically provided herein, the following terms
shall have the following meanings:
"AFFILIATE" when used with reference to a specified person or entity, means any
person or entity directly or indirectly controlling, controlled by or under
common control with the specified person or entity, while "control" in this
context means the direct or indirect ownership of at least 50% of the
outstanding voting securities of a person or entity.
"ANNUAL" means the period between January 1 and December 31, inclusive.
"ARENA ACTIVATION TECHNOLOGY" means an Arena proprietary approach, referred to
by Arena as "CART Technology", to identifying, selecting and altering a
region(s) within a G Protein Coupled Receptor that, when altered, leads to or
enhances ligand-independent constitutive activation of the altered receptor.
"ARENA LIBRARY COMPOUNDS" means approximately 80,000 Library Compounds
synthesized by Arena prior to the Effective Date or during the term of this
Agreement, or obtained by Arena from a Third Party prior to the Effective Date
or during the term of this Agreement, excluding: (i) any compound(s) licensed by
Arena to any Third Party prior to Screening of any Taisho Activated Receptor,
and/or (ii) any compound(s) that is the subject of any negotiation between Arena
and a Third Party prior to Screening of any Taisho Activated Receptor.
"ARENA PATENT RIGHTS" means all present and/or future patents (including
inventor's certificates) and all present and/or future applications (including
provisional applications) therefor throughout the world as the case may be, and
substitutions, extensions, reissues,
1
CONFIDENTIAL
renewals, divisions, continuations, or continuation-in-part thereof or therefor,
owned or controlled (either fully or partially) by Arena, or under which Arena
may grant licenses or sublicenses, to the extent they are directed to (1) Arena
Activation Technology applied to Taisho Selected GPCR(s) and/or (2) Taisho
Activated Receptor(s) and/or (3) CART Identified Compound(s) and/or (4) Drug
Product(s) and/or (5) Screening Assay(s).
"ARENA SCREENING" has the same meaning as set forth in Section 6.2(a) of this
Agreement.
"BACK-UP COMPOUND" means, as to EACH Taisho Activated Receptor, a subsequent
CART Identified Compound developed by Taisho and/or Taisho's Licensee(s)
subsequently to the preceding CART Identified Compound precedingly developed for
the same or similar therapeutic indication as the preceding CART Identified
Compound, that is developed after the discontinuation of the development of the
preceding CART Identified Compound or that is reserved at the lower stage of the
development than that of the preceding CART Identified Compound or that is
simultaneously developed with the preceding CART Identified Compound with the
intent to commercialize the subsequent CART Identified Compound only in the
event the development of the preceding CART Identified Compound is discontinued.
For the purpose of determination of such intent, a subsequent CART Identified
Compound shall be deemed Subsequent Compound but not Back-Up Compound if Phase 3
Clinical Study thereof is started prior to the discontinuation of the
development of the preceding CART Identified Compound.
"BEST REASONABLE COMMERCIAL EFFORTS" means efforts to achieve a designated
objective, which efforts are based upon reasonably prudent business factors and
considerations.
"CART IDENTIFIED COMPOUND(S)" means a compound, and/or a Derivative of a CART
Identified Compound, that has been identified as a modulator of a Taisho
Activated Receptor by Taisho or Taisho's Licensee(s) during the term of this
Agreement or by Arena Screening.
"CONTINUING UTILIZATION FEE" has the same meaning as set forth in Section 5.5 of
this Agreement.
"DERIVATIVE" of a first compound means a compound having the same core structure
as the first compound, that has been synthesized or conceived, and then
subsequently reduced to practice by Taisho, Taisho's Licensee(s) or Arena during
the term of this Agreement.
"DRUG PRODUCT" means a therapeutic product comprising a CART Identified
Compound.
"DRUG PRODUCT REVENUE" [**************************************************
******************************************************************************]
2
CONFIDENTIAL
"EFFECTIVE DATE" means the date first above written in this Agreement.
"ENDOGENOUS" means naturally occurring.
"EUROPEAN COUNTRY" means any of the following countries: United Kingdom,
Germany, France, Italy, and Spain.
"FDA" means the United States Food and Drug Administration.
"G PROTEIN COUPLED RECEPTOR" and "GPCR" means an Endogenous cell-surface
receptor defined by having three (3) intracellular loops, three (3)
extracellular loops, an amino terminus and a carboxy terminus.
"INFORMATION" has the same meaning as set forth in Section 12.1 of this
Agreement.
"IND" has the same meaning as set forth in 21 C.F.R. Section 312.20, including
any and all amendments, modifications or changes as may be made thereto in the
future, or the equivalent thereof in any applicable country within the
Territory.
"LIBRARY COMPOUNDS" means chemical compounds.
"MARKETING AUTHORIZATION" means the granting or authorization, by an appropriate
governmental agency, to commercialize a pharmaceutical product; by way of
example, the FDA is an appropriate governmental agency.
"MEASURED RESPONSE" when used in reference to the phrase "Taisho Activated
Receptor" means a signal measured based upon an assay end-point used to assess
the signal.
"NOTICE" has the same meaning as set forth in Section 18.11 of this Agreement.
"PHASE 2 CLINICAL STUDY" has the same meaning as set forth in 21 C.F.R.
Section 312.21(b), including any and all amendments, modifications or changes
thereto as may be made thereto in the future, or the equivalent thereof, in any
applicable country within the Territory.
"PHASE 3 CLINICAL STUDY" has the same meaning as set forth in 21 C.F.R.
Section 312.21(c), including any and all amendments, modifications or
changes thereto as may be made thereto in the future, or the equivalent
thereof, in any applicable country within the Territory.
"PARTY" means either Arena or Taisho, as the case may be; "Parties" means both
Arena and Taisho.
"REGULATORY AGENCY" includes, but is not be limited to, FDA, or similar
regulatory bodies in the Territory.
"SCREENING" means the process of contacting a chemical compound with a Taisho
Activated Receptor.
"SCREENING ASSAY" means an Arena assay approach for Screening that has been
validated based upon Successful Screening of a Taisho Activated Receptor.
"SCREENING ASSAY NOTICE" has the same meaning as set forth in Section 3.2 of
this Agreement.
3
CONFIDENTIAL
"SCREENING REQUEST" has the same meaning as set forth in Section 6.1 of this
Agreement.
"SUBSEQUENT COMPOUND" means, as to EACH Taisho Activated Receptor, a subsequent
CART Identified Compound developed by Taisho and/or Taisho's Licensee(s)
subsequently to the preceding CART Identified Compound preceedingly developed
for thesame or similar therapeutic indication as the preceding CART Identified
Compound, that is developed after the receipt of Marketing Authorization for the
preceding CART Identified Compound or that is simultaneously developed with the
preceding CART Identified Compound with the intent to commercialize both
Compounds. For the purpose of determination of such intent, a subsequent CART
Identified Compound shall be deemed Subsequent Compound if Phase 3 Clinical
Study thereof is started prior to the launch of the preceding CART Identified
Compound.
"SUCCESSFUL SCREENING" when used in conjunction with the phrase "Taisho
Activated Receptor" means that the results of the Screening has been positive
whereby at least one molecule that has been contacted with the Taisho Activated
Receptor reduces the Measured Response of the Taisho Activated Receptor by at
least two (2) standard deviations from the mean response of a screening plate
that includes that compound.
"TAISHO ACTIVATED RECEPTOR" means a Taisho Selected GPCR to which the Arena
Activation Technology has been applied.
"TAISHO ACTIVATED RECEPTOR NOTICE" has the same meaning as set forth in
Section 3.1 of this Agreement.
"TAISHO DEVELOPMENT" as applied to the phrase "CART Identified Compound", means
that Taisho management has approved research and development of a CART
Identified Compound with the intent of developing data based upon such CART
Identified Compound for inclusion within an IND.
"TAISHO'S LICENSEE(S)" means any person or entity, inclusive of Taisho's
Affiliates, to which Taisho has granted sublicenses as referred to in Article V.
"TAISHO SELECTED GPCR" has the same meaning as set forth in Section 2.1 of this
Agreement.
"TECHNICAL INFORMATION" means all information, trade secrets, know-how, methods
of manufacture, processes, documents and materials related to Taisho Activated
Receptor(s) and/or Screening Assay(s), and other proprietary information,
whether patentable or unpatentable, related to Taisho Activated Receptor(s)
and/or Screening Assay(s), including but not limited to, improvements, that are
owned, possessed by, or licensed to Arena, whether now existing or hereafter
developed or acquired during the term of this Agreement.
"TECHNOLOGY" means Arena Patent Rights and Technical Information.
"TERRITORY" means the world.
"THIRD PARTY" means any person or entity other than Taisho, Taisho's Licensee(s)
and Arena.
[THE REST OF THIS PAGE IS INTENTIONALLY BLANK]
4
CONFIDENTIAL
ARTICLE II
GPCR SELECTION BY TAISHO;
TECHNOLOGY ACCESS FEE
2.1 Subject to the terms and conditions of this Agreement, Taisho shall
be entitled to select up to a maximum of [**** (**)] GPCRs for inclusion in this
Agreement (each GPCR a "Taisho Selected GPCR"). The selection of any particular
GPCR for designation as a Taisho Selected GPCR shall be made exclusively by
Taisho, subject to the following:
(a) the selection by Taisho of up to [**** (**)] GPCRs, each
for designation as a Taisho Selected GPCR, shall be completed prior to the
expiration of the [*****] anniversary of the Effective Date; and
(b) during the selection period set forth above, when Taisho
requests information from Arena regarding GPCRs of possible interest to Taisho,
Arena shall provide Taisho with supportive information for Taisho's selection of
GPCRs and, in the event such GPCR(s) that have been activated by Arena
Activation Technology or that are intended to be activated by Arena Activation
Technology are available for Taisho's selection, Arena shall inform Taisho of
such GPCR(s) as candidates for Taisho Selected GPCR; and
(c) in the event that Taisho selects a GPCR that, as of the
date of such selection by Taisho, is the subject of another agreement or
obligation between Arena and a Third Party, such GPCR shall not be designated as
a Taisho Selected GPCR, and Arena shall provide Notice to Taisho that the
proposed GPCR can not be designated as a Taisho Selected GPCR.
2.2 Taisho Selected GPCRs shall be attached hereto as APPENDIX A, which
shall be updated when Taisho has selected a GPCR that is designated as a Taisho
Selected GPCR. As of the Effective Date, Taisho has selected [**** (**)] GPCR
for designation as a Taisho Selected GPCR. Accordingly, Taisho shall be
permitted to select up to [**** (**)] additional GPCRs for designation as Taisho
Selected GPCRs prior to the expiration of the [******] anniversary of the
Effective Date.
2.3 In consideration of the rights granted under this Article II,
within thirty (30) days of the Effective Date, Taisho shall provide to Arena a
one-time, non-refundable, non-creditable fee of
[*************************** (*******)].
[THE REST OF THIS PAGE IS INTENTIONALLY BLANK]
5
CONFIDENTIAL
ARTICLE III
ARENA ACTIVITIES
3.1 DEVELOPMENT OF TAISHO ACTIVATED RECEPTOR. Subject to the terms and
conditions of this Agreement, Arena agrees to use Best Reasonable Commercial
Efforts to apply Arena Activation Technology to EACH Taisho Selected GPCR to
establish a Taisho Activated Receptor. Upon creation of EACH Taisho Activated
Receptor, Arena shall provide Notice to Taisho ("Taisho Activated Receptor
Notice"), and such Taisho Activated Receptor Notice shall include data developed
by Arena evidencing that the Taisho Activated Receptor is constitutively active.
3.2 DEVELOPMENT OF SCREENING ASSAY. Subject to the terms and conditions
of this Agreement, Arena agrees to use Best Reasonable Commercial Efforts to
develop a Screening Assay incorporating EACH Taisho Activated Receptor. Upon
development of each Screening Assay, Arena shall provide Notice to Taisho
("Screening Assay Notice").
3.3 TRANSFER OF TAISHO ACTIVATED RECEPTOR AND TECHNICAL INFORMATION.
Subject to the terms and conditions of this Agreement, within thirty (30) days
of each Screening Assay Notice, Arena shall transfer to Taisho the applicable
Taisho Activated Receptor in the form and quantity agreed to in advance by the
Parties and a copy of all additional Technical Information owned or possessed by
Arena then applicable to such Taisho Activated Receptor and Screening Assay
incorporating such Taisho Activated Receptor. In the event the Successful
Screening using the Taisho Activated Receptor cannot be measured by Taisho in
accordance with the procedures and protocols used by Arena and provided to
Taisho as part of the applicable Technical Information, Arena shall cooperate
with Taisho in studying the cause and, if any defect in the Taisho Activated
Receptor or the Screening Assay transferred by Arena to Taisho is detected and
determined to have been caused by or effected by the activities of Arena, Arena
shall at its costs and expenses repair the defect or transfer a substitute
Taisho Activated Receptor and Screening Assay incorporating such substituted
Taisho Activated Receptor to Taisho.
3.4 ADDITIONAL SUPPLY. When requested by Taisho in writing, Arena shall
use its Best Reasonable Commercial Efforts to supply additional quantity of the
Taisho Activated Receptor within the time period requested by Taisho. If so
agreed by the Parties in writing, Arena shall supply additional Technical
Information owned or possessed by Arena to enable Taisho to reproduce and/or
increase the Taisho Activated Receptor for the purpose of the Screening.
[THE REST OF THIS PAGE IS INTENTIONALLY BLANK]
6
CONFIDENTIAL
ARTICLE IV
RESEARCH AND DEVELOPMENT FEES
4.1 RESEARCH AND DEVELOPMENT FEES. Taisho shall pay to Arena as follows
as research and development fees for Arena's activities set forth in Article
III.
(a) Within thirty (30) days after receipt of EACH Taisho
Activated Receptor Notice, Taisho shall provide Arena with a research and
development fee of [*************************** (*******)]. The Parties
acknowledge and agree that the maximum amount that Taisho would be required to
pay to Arena under this Section 4.1 (a) is
[****************************************** (**********)] in the event that
Taisho selects up to [****] (**)]GPCRs for designation as Taisho Selected GPCRs
prior to the second anniversary of the Effective Date, and each Taisho Selected
GPCR is the subject of an Activation Receptor Notice. As to [******** (**)
Taisho Selected GPCR selected as of the Effective Date, Taisho Activated
Receptor thereof has been established as of the Effective Date and the payment
under this Section 4.1 (a) shall be due and payable within thirty (30) days of
the Effective Date.
(b) Within thirty (30) days after receipt of EACH Taisho
Activated Receptor and Screening Assay, Taisho shall provide Arena with a
research and development fee of [*************************** (*******)]. The
Parties acknowledge and agree that the maximum amount that Taisho would be
required to pay to Arena under this Section 4.1 (b) is
[*********************************** (*******)] in the event that Taisho selects
[***** (**)] GPCRs for designation as Taisho Selected GPCRs prior to the
[*******] anniversary of the Effective Date, and each Taisho Selected GPCR is
the subject of a Screening Assay Notice.
(c) As to EACH Taisho Activated Receptor, within thirty (30)
days after the earlier of (i) completion of the Screening by Taisho of
approximately [*****] Library Compounds or (ii) completion of the Arena
Screening, Taisho shall provide Arena with a research and development fee of
[*************************** (*******)]. The Parties acknowledge and agree that
the maximum amount that Taisho would be required to pay to Arena under this
Section 4.1 (c) is [*************************** (*******)] in the event that
Taisho selects [**** (**)] GPCRs for designation as Taisho Selected GPCRs prior
to the [*****] anniversary of the Effective Date, and each Taisho Selected GPCR
is the subject of a Screening Assay Notice, and each Taisho Activated Receptor
is the subject of the Screening by Taisho of approximately [****] Library
Compounds or the Arena Screening.
4.2 PAYMENT UNDERSTANDING. Taisho acknowledges and agrees that any
payment due under this Article IV shall be made as required and that once made,
such payment shall be non-refundable and non-creditable. Within 30 days of the
receipt by Arena of each payment, Arena shall provide to Taisho a statement with
supportive documents sufficiently verifying the costs and expenses incurred by
Arena regarding the corresponding research and development activities.
7
CONFIDENTIAL
ARTICLE V
LICENSE GRANT
5.1 ARENA LICENSE. Arena hereby grants to Taisho the following with
respect ONLY to the Taisho Activated Receptor that is the subject of the
Screening Assay Notice:
(a) an exclusive right and license under the Technology,
exclusive even as to Arena but subject to the provisions of Section 5.5 and
Article VI, to use, have used, sell, have sold, import, have imported, further
develop, improve and otherwise exploit in any manner the Taisho Activated
Receptor, for the purpose of identification of CART Identified Compound(s) in
the Territory including the right to sublicense the rights granted to Taisho by
Arena hereunder, and
(b) an exclusive right and license under the Technology,
exclusive even as to Arena, to develop, manufacture, have manufactured, promote,
market, sell and distribute CART Identified Compound(s) and/or Drug Product(s)
in the Territory including the right to sublicense the rights granted to Taisho
by Arena hereunder.
5.2 SUBLICENSE. In the event that Taisho sublicenses any right granted
by Arena hereunder, Taisho warrants that it shall notify Arena within one (1)
month of the effective date of any such sublicense agreement; at all times
during the term of this Agreement, Taisho shall have an affirmative obligation
to make any such payments to Arena that Taisho would be required to make to
Arena hereunder, irrespective of the financial situation of any such Taisho's
Licensee(s).
5.3 IMPROVEMENTS.
(a) Taisho shall notify Arena, in writing, of any improvement
discovered or developed by Taisho and/or Taisho's Licensee(s) related to the
Technology.
(b) Arena shall notify Taisho, in writing, of any improvement
discovered or developed by Arena related to the Technology within one (1) month
of the discovery or development of such improvement.
(c) The obligations of Sections 5.3(a) and (b) of this
Agreement shall be continuing throughout the term of this Agreement. During the
term of this Agreement, Taisho shall be entitled to use any such improvement in
accordance with the provisions of Sections 5.1 and 5.2 of this Agreement.
(d) Subject to Section 5.1 and except as specifically provided
for in Section 5.3(e) hereof, Arena shall have a royalty-free, non-exclusive
right and license to use all improvements of Taisho and/or Taisho's Licensee(s)
referred to in Section 5.3(a) hereof and to disclose and sublicense the same to
its licensees, if any.
(e) Both Parties acknowledge and agree that Arena has
exclusive ownership of the Technology existing as of the Effective Date and any
improvement thereof hereafter discovered or developed by Arena and that Taisho
has exclusive ownership of or control over any improvement of the Technology
hereafter discovered or developed by Taisho and/or Taisho's Licensee(s).
8
CONFIDENTIAL
5.4 NO WARRANTY. NEITHER PARTY MAKES ANY REPRESENTATION THAT ANY TAISHO
SELECTED GPCR OR TAISHO ACTIVATED RECEPTOR OR SCREENING ASSAY TRANSFERRED BY
ARENA TO TAISHO, OR USED BY ARENA ON BEHALF OF TAISHO IN ACCORDANCE WITH THIS
AGREEMENT, WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER
PROPRIETARY RIGHT OF ANY OTHER PERSON. NEITHER PARTY MAKES ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY,
EXPRESS OR IMPLIED, WITH RESPECT TO ANY TAISHO SELECTED GPCR OR TAISHO ACTIVATED
RECEPTOR OR SCREENING ASSAY, AS THE CASE MAY BE.
5.5 CONTINUING UTILIZATION FEE.
(a) For EACH Taisho Activated Receptor, Taisho shall retain
exclusive rights, for a period Taisho continues the identification and/or
development of CART Identified Compound(s) with its Best Reasonable Commercial
Efforts, in and to such Taisho Activated Receptor when Taisho provides Arena
with a Continuing Utilization Fee of [*************************** (*******)]
before the expiration of [**************** (*******)] days from the date of
transfer of such Taisho Activated Receptor to Taisho ("Transfer Anniversary
Date").
(b) The Parties acknowledge and understand that once made,
EACH Continuing Utilization Fee shall be non-refundable and non-creditable, and
that the maximum amount that Taisho would be required to pay to Arena under this
Section 5.5 is [********************************************* (*******)] in the
event that (i) Taisho selects [****** (***)] GPCRs for designation as Taisho
Selected GPCRs prior to the [******] anniversary of the Effective Date, whereby
each Taisho Selected GPCR is the subject of a Screening Assay Notice, and (ii)
Taisho provides a Continuing Utilization Fee for each Taisho Activated Receptor,
and that, when Taisho does not provide a Continuing Utilization Fee for a Taisho
Activated Receptor, the right and license granted to Taisho under Section 5.1(a)
shall be converted to non-exclusive right and license after the Transfer
Anniversary Date.
ARTICLE VI
SCREENING BY ARENA
6.1 TAISHO SCREENING REQUEST. During the term of this Agreement, Taisho
is entitled to provide Notice to Arena requesting that Arena conduct Screening
efforts for Taisho using a Taisho Activated Receptor, Screening Assay and Arena
Library Compounds ("Screening Request").
6.2 SCREENING FEE. With EACH Screening Request made by Taisho under
Section 6.1 of this Agreement, Taisho shall simultaneously provide to Arena a
Screening Fee of [*************************** (*******)]. Upon receipt of such
Screening Fee, the following shall apply:
(a) For EACH Taisho Activated Receptor and its corresponding
Screening Assay, Arena, using Best Reasonable Commercial Efforts, shall utilize
the Taisho Activated Receptor and the Screening Assay for Screening using Arena
Library Compounds ("Arena Screening").
9
CONFIDENTIAL
(b) For EACH Taisho Activated Receptor subject to Arena
Screening, Arena shall use Best Reasonable Commercial Efforts to identify at
least [*** (**)] CART Identified Compound.
(c) The Parties acknowledge and understand that once made,
EACH Screening Fee shall be non-refundable and non-creditable, and that the
maximum amount that Taisho would be required to pay to Arena under this Section
6.2 is [************************ (*******)] in the event that Taisho provides
[**** (**)] Screening Requests to Arena.
6.3 TAISHO SCREENING. In the event that Taisho does not provide a
Screening Request to Arena for any, or all, Taisho Activated Receptor(s), Taisho
shall use Best Reasonable Commercial Efforts to conduct Screening of
approximately [****] Library Compounds obtained by Taisho using the Taisho
Activated Receptor. When requested by Taisho in writing, Arena shall use its
Best Reasonable Commercial Efforts to assist Taisho in setting-up the Screening
Assays at Taisho's facility within the time period(s) requested by Taisho.
Taisho agrees to reimburse Arena for the reasonable out-of-pocket costs
associated with the assistance of Taisho with its Screening.
ARTICLE VII
CLINICAL DEVELOPMENT
OF CART IDENTIFIED COMPOUND
7.1 For each Taisho Activated Receptor, Taisho shall use Best
Reasonable Commercial Efforts to develop into clinical development stage at
least [*** (**)] CART Identified Compound. Arena acknowledges and agrees that
Taisho shall have sole discretion to: (i) determine which CART Identified
Compound to develop as a first Drug Product, Back-Up Compound or Subsequent
Compound; and (ii) whether or not to continue development of any CART Identified
Compound or Drug Product.
7.2 In consideration of the right and license granted to Taisho
hereunder with respect to each Taisho Activated Receptor, Taisho agrees to pay
to Arena the following clinical milestone fees for each CART Identified Compound
as long as this Agreement is in full force and effect. For a CART Identified
Compound, the payment shall be made only at the first occurrence, if any, of a
milestone set forth below as to the Drug Product first applicable to such
milestone that incorporate the CART Identified Compound, regardless of
formulation and/or indication of the Drug Product. Provided, however, the
Parties agree that (i) as long as the development of preceding CART Identified
Compound is being continued, Taisho shall be exempted from the payments of
milestone fees for Back-Up Compound and (ii) any milestone payment made by
Taisho to Arena for the preceding CART Identified Compound may be fully credited
by Taisho against milestone payments for Back-Up Compound that shall become due
by Taisho when: (i) the development of the preceding CART Identified Compound is
discontinued by Taisho and (ii) Back-Up Compound replaces the withdrawn
preceding CART Identified Compound (such replacement shall be notified in
writing to Arena by Taisho).
(a) ONE TIME IND DECISION FEE. Taisho shall provide Notice to
Arena of its decision to implement Taisho Development of a CART Identified
10
CONFIDENTIAL
Compound. Within thirty (30) days of the date of such Notice, Taisho shall
provide to Arena a One Time IND Decision Fee of [***************************
(*******)].
(b) ONE TIME IND MILESTONE. Upon the filing of the first IND
in the Territory for a CART Identified Compound, Taisho shall provide to Arena a
One Time IND Milestone of [********************* (*******)] within thirty (30)
days of such filing.
(c) PHASE 2 CLINICAL STUDY MILESTONE. Within thirty (30) days
of the dosing of the first human in a Phase 2 Clinical Study in the Territory of
a Drug Product, Taisho shall provide to Arena a Phase 2 Clinical Study Milestone
of [*************************** (*******)].
(d) PHASE 3 CLINICAL STUDY MILESTONE. Within thirty (30) days
of the dosing of the first human in a Phase 3 Clinical Study in the Territory of
a Drug Product, Taisho shall provide to Arena a Phase 3 Clinical Study Milestone
of [*************************** (*******)].
7.3 The Parties acknowledge and agree that the maximum amount that
Taisho would be required to pay to Arena under the provisions of Article VII of
this Agreement as to each CART Identified Compound (inclusive of Back-Up
Compound(s) thereof) would be [*************************** (*******)].
7.4 Notwithstanding anything to the contrary herein contained, payments
of milestone fees for the Subsequent Compound shall only be subject to the
provisions of Article IX of this Agreement, provided, that the provisions of
Article IX of this Agreement shall only apply when, and to the extent that,
Taisho has made all applicable payments for the preceding CART Identified
Compound under Article VII of this Agreement.
7.5 NEITHER PARTY MAKES ANY REPRESENTATION TO THE OTHER THAT ANY CART
IDENTIFIED COMPOUND OR ANY DRUG PRODUCT WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK OR OTHER PROPRIETARY RIGHT OF ANY OTHER PERSON. NEITHER PARTY MAKES
ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER
WARRANTY, EXPRESS OR IMPLIED, TO THE OTHER WITH RESPECT TO ANY CART IDENTIFIED
COMPOUND OR ANY DRUG PRODUCT.
[THE REST OF THIS PAGE IS INTENTIONALLY BLANK]
11
CONFIDENTIAL
ARTICLE VIII
MARKETING AUTHORIZATION
8.1 Taisho shall use Best Reasonable Commercial Efforts to seek
Marketing Authorization for a Drug Product developed using a Taisho Activated
Receptor in the United States, Japan and European County.
8.2 In consideration of the right and license granted to Taisho
hereunder, Taisho agrees to pay to Arena the following marketing milestone fees
for each CART Identified Compound as long as this Agreement is in full force and
effect. As long as Taisho is using Taisho Activated Receptor, Screening Assay,
CART Identified Compound and/or Drug Candidate, then all such payments shall be
made by Taisho to Arena, even if this Agreement is not in full force and effect
at the time that such payment is due. For a CART Identified Compound, the
payment shall be made only at the first occurrence, if any, of a milestone set
forth below as to the Drug Product first applicable to such milestone that
incorporate the CART Identified Compound, regardless of formulation and/or
indication of the Drug Product.
(a) UNITED STATES. For the first Drug Product that has received
Marketing Authorization in the United States, Taisho shall provide Arena with an
approval fee of [******************** (*******)] within thirty (30) days of
receipt of notification of such Marketing Authorization.
(b) JAPAN. For the first Drug Product that has received
Marketing Authorization in Japan, Taisho shall provide Arena with an approval
fee of [**************** (*******)] within thirty (30) days of receipt of
notification of such Marketing Authorization.
(c) EUROPEAN COUNTRY. For the first Drug Product that has
received Marketing Authorization in the first European Country, Taisho shall
provide Arena with an approval fee of [******************* (*******)] within
thirty (30) days of receipt of notification of such Marketing Authorization.
8.3 The Parties acknowledge and agree that the maximum amount that
Taisho would be required to pay to Arena under the provisions of Article VIII of
this Agreement as to each CART Identified Compound would be
[*************************** (*******)].
8.4 Notwithstanding anything to the contrary herein contained, payments
of marketing milestone fees for the Subsequent Compound shall only be subject to
the provisions of Article IX of this Agreement, provided, that the provisions of
Article IX of this Agreement shall only apply when, and to the extent that,
Taisho has made all applicable payments under Article VIII of this Agreement.
12
CONFIDENTIAL
8.5 DRUG MASTER FILE. Taisho shall be responsible for the preparation
and submission of a drug master file with FDA (as set forth in 21 C.F.R
Section 314.420(b)), or any similar file required by any Regulatory Agency.
Arena shall, upon request by Taisho, give all reasonable assistance to Taisho
to enable Taisho to develop, and obtain Marketing Authorization for Drug
Product(s).
ARTICLE IX
CLINICAL DEVELOPMENT
OF SUBSEQUENT COMPOUNDS
9.1 Arena acknowledges and agrees that Taisho shall have sole
discretion to determine whether or not Taisho shall: (i) develop any Subsequent
Compound, and (ii) to continue development of any Subsequent Compound.
9.2 In consideration of the right and license granted to Taisho
hereunder with respect to each Taisho Activated Receptor, Taisho agrees to pay
to Arena the following clinical and marketing milestone fees for each Subsequent
Compound as long as this Agreement is in full force and effect. As long as
Taisho is using Taisho Activated Receptor, Screening Assay, CART Identified
Compound and/or Drug Candidate, then all such payments shall be made by Taisho
to Arena, even if this Agreement is not in full force and effect at the time
that such payment is due. For a Subsequent Compound, the payment shall be made
only at the first occurrence, if any, of a milestone set forth below as to the
Drug Product first applicable to such milestone that incorporate the Subsequent
Compound, regardless of formulation and/or indication of the Drug Product.
Provided, however, the Parties agree that Taisho shall be exempted from the
payments of the following milestone fees until the earlier of (i) Taisho obtains
the Marketing Authorization of the preceding CART Identified Compound or (ii)
Taisho express its intent to commercialize both the preceding CART Identified
Compound and the Subsequent Compound or (iii) the subsequent CART Identified
Compound is deemed the Subsequent Compound but not the Back-Up Compound
according to the definitions thereof, and that if any milestone(s) set forth
below occur during such exemption period, the corresponding milestone fee(s)
shall be paid in a lump sum within thirty (30) days of the end of such exemption
period.
(a) REDUCED IND DECISION FEE. Taisho shall provide Notice to
Arena of its decision to implement Taisho Development of a Subsequent Compound.
Within thirty (30) days of the date of such Notice, Taisho shall provide to
Arena a Reduced IND Decision Fee of [*************************** (*******)].
(b) REDUCED IND MILESTONE. Upon the filing of an IND in the
Territory for a Subsequent Compound, Taisho shall provide to Arena a Reduced IND
Milestone of [*************************** (*******)] within thirty (30) days of
such filing.
13
CONFIDENTIAL
(c) REDUCED PHASE 2 CLINICAL STUDY MILESTONE. Within thirty
(30) days of the dosing of the first human in a Phase 2 Clinical Study in the
Territory of a Drug Product comprising a Subsequent Compound, Taisho shall
provide to Arena with a Reduced Phase 2 Clinical Study Milestone of
[*********************** (*******)].
(d) REDUCED PHASE 3 CLINICAL STUDY MILESTONE. Within thirty
(30) days of the dosing of the first human in a Phase 3 Clinical Study in the
Territory of a Drug Product comprising a Subsequent Compound, Taisho shall
provide to Arena with a Reduced Phase 3 Clinical Study Milestone of
[*************************** (*******)].
(e) UNITED STATES. For a Drug Product comprising a Subsequent
Compound that has received Marketing Authorization in the United States, Taisho
shall provide Arena with an approval fee of [******************* (*******)]
within thirty (30) days of receipt of notification of such Marketing
Authorization.
(f) JAPAN. For a Drug Product comprising a Subsequent Compound
that has received Marketing Authorization in Japan, Taisho shall provide Arena
with an approval fee of [******************* (*******)] within thirty (30) days
of receipt of notification of such Marketing Authorization.
(g) EUROPEAN COUNTRY. For a Drug Product comprising a
Subsequent Compound that has received Marketing Authorization in the first
European Country, Taisho shall provide Arena with an approval fee of
[******************** (*******)] within thirty (30) days of receipt of
notification of such Marketing Authorization.
9.3 The Parties acknowledge and agree that the maximum amount that
Taisho would be required to pay to Arena under the provisions of Section 9.2 of
this Agreement as to each Subsequent Compound would be
[*************************** (*******)].
9.4 Arena acknowledges and agrees that in the event that Taisho
discontinues development of a Subsequent Compound prior to the Market
Authorization of the preceding CART Identified Compound, then any milestone
payments otherwise due by Taisho for such Subsequent Compound under this
Agreement shall not be required to be made by Taisho.
9.5 NEITHER PARTY MAKES ANY REPRESENTATION TO THE OTHER THAT SUBSEQUENT
COMPOUND WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER PROPRIETARY
RIGHT OF ANY OTHER PERSON. NEITHER PARTY MAKES ANY WARRANTY OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED,
TO THE OTHER WITH RESPECT TO ANY SUBSEQUENT COMPOUND.
14
CONFIDENTIAL
ARTICLE X
ROYALTY PAYMENTS
10.1 ROYALTY PAYMENT. In consideration of the right and license granted
to Taisho hereunder with respect to each Taisho Activated Receptor, for EACH
Drug Product that has received Marketing Authorization, Taisho shall provide
Arena with a royalty payment based on Annual Drug Product Revenue as set forth
below for a period ending upon the expiration of [***** (***)] years from the
Effective Date; such royalty payment shall be made within three (3) months of
December 31 for the Annual period to which the Annual Drug Product Revenue
applies:
(a) [***** (***)] of the portion of Annual Drug Product
Revenue between [*************** ] and [********************]; and
(b) [***** (***)] of the portion of Annual Drug Product
Revenue between [*************** ] and [********************]; and
(c) [***** (***)] of the portion of Annual Drug Product
Revenue between [*************** ] and [********************]; and
(d) [***** (***)] of the portion of Annual Drug Product
Revenue above [*************** ].
(e) By way of example and not limitation, in the event that
Annual Drug Product Revenue for a Drug Product is [**************], Taisho shall
provide a royalty payment to Arena of [***********], based upon an aggregate of:
[******] (Section 10.1(a) component); [******] (Section 10.1(b) component);
[*********] (Section 10.1(c) component); and [********] (Section 10.1(d)
component).
10.2 AUDIT. In order to verify the completeness and correctness of Drug
Product Revenue, Taisho shall maintain up to date books and records and Arena
shall have the right to conduct, through independent certified public
accountants, at its own cost and at any reasonable time during business hours,
not more often than once each Annual period for not more than three (3) previous
years, and upon reasonable prior notice, an audit of the accounting procedures
and records of Taisho in computing and calculating royalty payment for Annual
Drug Product Revenue due hereunder. The auditor shall make available to Taisho
and Arena a report enumerating the period covered by the audit of Drug Product
Revenue computed and calculated by the auditor. The costs of such audit shall be
borne by Taisho in the event that a discrepancy of more than five per cent (5%)
is discovered through such audit.
[THE REST OF THIS PAGE IS INTENTIONALLY BLANK]
15
CONFIDENTIAL
ARTICLE XI
PAYMENT ARRANGEMENT
The Parties acknowledge and agree that any and all payments to be made
by Taisho to Arena under this Agreement are to be (i) in United States Dollars
and (ii) in full as indicated; provided, however, that any income or other tax
which Taisho is required to pay or withhold on behalf of Arena with respect to
payments payable to Arena hereunder shall be deducted from the amounts of such
payments. Taisho agrees to reasonably cooperate with Arena in obtaining a
foreign tax credit in the U.S. with respect to such payment due to Arena.
ARTICLE XII
CONFIDENTIALITY
12.1 Each party shall neither disclose to any Third Party any and all
of the information ("Information") disclosed by the other Party hereunder and
under the Mutual Non-Disclosure Agreement of August 31, 1999 between Arena and
Taisho, nor permit any such Third Party to have access to such Information, nor
use such Information for any purpose other than for purpose of this Agreement,
without the prior written consent of the other Party.
12.2 The receiving Party's obligations under Article 12.1 hereof shall
not apply, with respect to any of such Information to the extent that the
receiving Party can establish by competent proof that such Information:
(a) is published, known publicly, or is already in the public
domain at the time of receipt of it by the receiving Party;
(b) is published, becomes known publicly or becomes a part of
the public domain by publication or otherwise after the time of receipt of it by
the receiving Party, except by breach of this Agreement by the receiving Party;
(c) is obtained from a Third Party after the receipt of it by
the receiving Party, provided, however, that said Third Party has not obtained
it directly or indirectly from the disclosing Party;
(d) is in the receiving Party's possession on the date of the
receipt of it and was not acquired directly or indirectly from the disclosing
Party; or
(e) is subsequently developed by the receiving Party
independent of the information received hereunder, as evidenced by competent
written records established by the receiving Party.
16
CONFIDENTIAL
12.3 Notwithstanding anything to the contrary in this Agreement, the
receiving Party shall be entitled to disclose such Information (i) to the extent
required by applicable law or court order provided that the receiving Party
furnishes the disclosing Party with written notice of such request, in advance
of any such disclosure of the Information or (ii) to a government agency,
regulatory authority, clinical research organization, clinical investigator or
other Third Party to whom disclosure is necessary for development of the CART
Identified Compound in connection with drug development, approval or
registration of the CART Identified Compound and/or Drug Product.
The foregoing obligations of confidentiality shall survive for five (5) years
after any termination or expiration of this Agreement.
ARTICLE XIII
PATENT INFRINGEMENT AND ENFORCEMENT
13.1 NOTIFICATION OF INFRINGEMENT. Each Party shall promptly provide
Notice to the other of any infringement (of which it becomes aware) of the
intellectual property rights including patent rights on any Taisho Activated
Receptor(s) and/or Screening Assay(s) and/or CART Identified Compound(s) and/or
Drug Product(s) by any Third Party and shall provide the other with any
available evidence of such infringement of which the Party is aware.
13.2 SUIT FOR INFRINGEMENT.
(a) During the term of this Agreement, Arena shall be
responsible for enforcement of the Arena Patent Rights including, but not
limited to, the bringing of an action for patent infringement, selection of the
forum for such action, and counsel, settlement of any such action, and the costs
devoted to such action. Taisho agree to provide reasonable assistance except for
financial assistance to Arena in the enforcement of Arena Patent Rights and
Taisho may join such action as initiated by Arena with counsel at its own
expense and seek its own damages and other relief. If, within ninety (90) days
of Taisho's giving notice to Arena of a Third Party infringement in the
Territory, Arena fails to institute the infringement suit that Taisho reasonably
feels is required, Taisho may institute such infringement proceedings against
said Third Party at its expense and Taisho shall have the right to receive all
the amounts payable by said Third Party as a result of such proceedings.
(b) In the event a claim of patent infringement is made
against Taisho by a Third Party in the Territory by reasons of Taisho's
commercial activities hereunder, Taisho and Arena shall meet to analyze the
infringement claim and avoidance of the same. If it is necessary to obtain an
appropriate license from such a Third Party, the Parties shall, in negotiating
such a license, make every efforts to minimize the amount of license fees and/or
royalties payable to such Third Party and (i) in case that such license is
related to Arena Activation Technology, Arena shall be responsible for such
license fees and/or royalties, (ii) in case that such license is related to
Taisho Selected GPCR and/or Taisho Activated Receptor and/or Screening Assay,
and/or CART Identified Compound, and/or Drug Product, Taisho shall be
responsible for such license fees and/or royalties,
17
CONFIDENTIAL
ARTICLE XIV
REPRESENTATION AND WARRANTIES
14.1 REPRESENTATIONS AND WARRANTIES OF TAISHO. Taisho represents and
warrants to Arena as follows:
(a) The execution and delivery of this Agreement have been
duly and validly authorized, and all necessary action has been taken to make
this Agreement a legal, valid and binding obligation of Taisho enforceable in
accordance with its terms.
(b) The execution and delivery of this Agreement and the
performance by Taisho of its obligations hereunder will not contravene or result
in the breach of the Certificate of Incorporation or Bylaws of Taisho or result
in any material breach or violation of or material default under any material
agreement, indenture, license, instrument or understanding or, to the best of
its knowledge, result in breach of any law, rule, regulation, statute, order or
decree, to which Taisho is a party or of which it or any of its property is
subject.
14.2 REPRESENTATIONS AND WARRANTIES OF ARENA. Arena represents and
warrants to Taisho as follows:
(a) The execution and delivery of this Agreement have been
duly and validly authorized, and all necessary action has been taken to make
this Agreement a legal, valid and binding obligation of Arena enforceable in
accordance with its terms.
(b) The execution and delivery of this Agreement and the
performance by Arena of its obligations hereunder will not contravene or result
in the breach of the Certificate of Incorporation or Bylaws of Arena or result
in any material breach or violation of or material default under any material
agreement, indenture, license, instrument or understanding or, to the best of
its knowledge, result in breach of any law, rule, regulation, statute, order or
decree, to which Arena is a party or of which it or any of its property is
subject.
ARTICLE XV
INDEMNITY
15.1 INDEMNIFICATION BY TAISHO. Taisho will indemnify and hold harmless
Arena and its Affiliates, employees, officers, directors, shareholders and
agents (an "Arena Indemnified Party") from and against all liability, loss,
damages, costs and expenses (including reasonable attorneys' fees) which Arena
Indemnified Party may incur, suffer or be required to pay resulting from or
arising in connection with (i) the breach by Taisho of any agreement, covenant,
representation or warranty of Taisho obtained in this Agreement, or (ii)
negligence or omission of Taisho.
18
CONFIDENTIAL
15.2 INDEMNIFICATION BY ARENA. Arena will indemnify and hold harmless
Taisho and its Affiliates, Taisho's Licensees, employees, officers, directors,
shareholders and agents (an "Taisho Indemnified Party") from and against all
liability, loss, damages, costs and expenses (including reasonable attorneys'
fees) which Taisho Indemnified Party may incur, suffer or be required to pay
resulting from or arising in connection with (i) the breach by Arena of any
agreement, covenant, representation or warranty of Arena obtained in this
Agreement, or (ii) negligence or omission of Arena.
15.3 CONDITIONS TO INDEMNIFICATION. The obligations of the indemnifying
Party under Sections 15.1 and 15.2 of this Agreement are conditioned upon the
prompt Notice to the indemnifying Party of any of the aforementioned suits or
claims in writing within fifteen (15) days after receipt of notice by the
indemnified Party of such suit or claim. The indemnifying Party shall have the
right to assume the defense of any such suit or claim unless, in the reasoned
judgment of the indemnified Party, such suit or claim involves an issue or
matter which could have a materially adverse effect on the business, operations
or assets of the indemnified Party, in which event the indemnified Party may
participate in the defense of such suit or claim at its sole cost and expense.
The provision for indemnification shall be void and there shall be no liability
against a indemnified Party as to any suit or claim for which settlement or
compromise or an offer of settlement or compromise is made without the prior
consent of the indemnifying Party.
ARTICLE XVI
TERMINATION
16.1 BREACH. Failure by either Party to comply with any of its material
obligations contained in this Agreement shall entitle the other Party to give
Notice to the Party in default specifying the nature of the default and
requiring it to cure such default. If such default is not cured within two (2)
months after receipt of such Notice, the notifying Party shall be entitled,
without prejudice to any of its other rights conferred on it by this Agreement,
to terminate this Agreement and the licenses granted to the breaching Party
hereunder with immediate effect by giving notice to such termination. The right
of either Party to terminate this Agreement as herein provided shall not be
affected in any way by its waiver of, or failure to take action with respect to,
any previous default.
16.2 DURATION OF THIS AGREEMENT.
(a) This Agreement shall become effective from the Effective
Date and continue to be in effect until expiration of Taisho's obligation of
royalty payment hereunder, if any; such obligation of royalty payment shall be
twenty (20) years from the Effective Date. Thereafter, all licenses or
sublicenses granted hereunder shall become fully paid-up irrecoverable license.
(b) Either Party shall be entitled to terminate this
Agreement in the event of
(1) insolvency of the other Party or
commencement of bankruptcy proceedings by
such Party; or
(2) dissolution of the other Party by that
Party, or liquidation of such Party by that
Party.
19
CONFIDENTIAL
(c) The Parties agree that in the event that Taisho
sublicenses any of the rights granted to it under this Agreement to a Third
Party, such sublicense shall include provisions whereby if such sublicensee(s)
becomes insolvent, commences bankruptcy proceedings, dissolves, and/or
liquidates its assets, any and all rights granted by Taisho to such
sublicensee(s) shall automatically revert back to Taisho.
16.3 ACCRUED RIGHTS; SURVIVING OBLIGATIONS. Termination or expiration
of this Agreement for any reason shall be without prejudice to any rights which
shall have accrued to the benefit of either Party prior to such termination or
expiration, nor shall such termination or expiration relieve either Party from
obligations which are expressly indicated to survive termination or expiration
of this Agreement.
ARTICLE XVII
RELATIONSHIP OF THE PARTIES
Nothing in this Agreement is intended or shall be deemed to constitute
a partnership, agency, employer-employee, or joint venture relationship between
the Parties. All activities by each Party hereunder shall be provided as an
independent contractor. No Party shall incur any debts or make any commitments
for the other, except to the extent, if at all, specifically provided herein.
ARTICLE XVIII
MISCELLANEOUS PROVISIONS
18.1 LIMITATIONS ON ASSIGNMENT. Neither this Agreement nor any interest
hereunder shall be assignable or transferable by Arena or Taisho without the
prior written consent of the other Party.
18.2 FURTHER ACTS AND INSTRUMENTS. Each Party hereto agrees to execute,
acknowledge and deliver such further instruments and to do all such other acts
as may be necessary or appropriate to carry out the purpose and intent of this
Agreement.
18.3 ENTIRE AGREEMENT. This Agreement constitutes and contains the
entire agreement of the Parties and supersedes any and all prior negotiations,
correspondence, understandings, Letters of Intent and agreements between the
Parties respecting the subject matter hereof. This Agreement may be amended or
modified or one or more provisions hereof waived only by a written instrument
signed by the Parties.
18.4 SEVERABILITY. If one or more provisions of this Agreement are held
to be unenforceable under applicable law, such provision shall be excluded from
this Agreement and the balance of this Agreement shall be interpreted as if such
provision were so excluded.
18.5 CAPTIONS. The captions to this Agreement are for convenience only
and are to be of no force or effect in construing and interpreting the
provisions of this Agreement.
18.6 FORCE MAJEURE. Neither Party shall be liable to the other for loss
or damages, or have any right to terminate this Agreement for any default or
delay, attributable to any act of God, flood, fire, explosion, breakdown or
plant strike, lockout,
20
CONFIDENTIAL
labor dispute, casualty, accident, war, revolution, civil commotion, act of a
public enemy, blockage, embargo, injunction, law, order, proclamation,
regulation, ordinance, demand or requirement of any government or subdivision,
authority or representative of any government, or any other cause beyond the
reasonable control of such Party.
18.7 NO TRADE NAME OR TRADEMARK LICENSE.
(a) No right, express or implied, is granted by this Agreement
to Taisho, Taisho collaborators or Taisho's Licensees to use in any manner the
name "Arena," "Arena Pharmaceuticals," "CART" or any trade name or trademark of
Arena in any business dealing which is not directly connected with the
performance of this Agreement; provided, however, that Taisho shall have the
right to use or disclose the name Arena only to the extent and the manner as may
be required by law.
(b) No right, express or implied, is granted by this Agreement
to Arena, Arena collaborators or Arena licensees to use in any manner the name
"Taisho" or any trade name or trademark of Taisho in any business dealing which
is not directly connected with the performance of this Agreement; provided,
however, that Arena shall have the right to use or disclose the name Taisho only
to the extent and the manner as may be required by law.
(c) During the term of this Agreement, the Parties may issue a
press release regarding the acceptance of this Agreement by the Parties with
prior written consent of the other Party on the contents of such release, which
consent shall not be unreasonably withheld (it is not necessary to obtain the
consent of the other Party for disclosing the information regarding this
Agreement which a Party is required by law to disclose).
18.8 GOVERNING LAW; CONSENT TO JURISDICTION. This Agreement shall be
governed by and construed under applicable federal law of the United States of
America and the laws of the State of California, excluding any conflict of law
provisions. Each Party hereto hereby voluntarily and irrevocably waives trial by
jury in any action or proceeding brought in connection with this Agreement, any
of the other transaction documents or any of the transactions contemplated
hereby or thereby. Each Party hereby expressly waives any and all rights to
bring any suit, action or other proceeding in or before any court or tribunal
other than arbitration court of the International Chamber of Commerce and
covenants that it shall not seek in any manner to resolve any dispute other than
as set forth in this Section 18.8 or to challenge or set aside any decision,
award or judgment obtained in accordance with the provisions hereof. Each Party
hereby expressly waives any and all objections it may have to venue, including,
without limitation, the inconvenience of such forum, in any of such courts. In
addition, the service of process regarding the arbitration shall be subject to
the rules of arbitration of the International Chamber of Commerce or applicable
laws. The Parties further agree that any dispute resolution initiated by Taisho
under this Section 18.8 shall take place in San Diego, California (U.S.A.) and
that any dispute resolution initiated by Arena under this Section 18.8 shall
take place in Tokyo, JAPAN
18.9 EXPENSES. Except as otherwise provided herein, each Party hereto
shall bear its legal and other expenses incurred in connection with the
negotiation, execution, delivery and performance of this Agreement.
21
CONFIDENTIAL
18.10 COUNTERPARTS. This Agreement shall be executed in two
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
18.11 NOTICE. Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the Party to be notified or upon
deposit with the registered or certified mail in the country of residence of the
Party giving the notice, postage prepaid, or upon deposit with an
internationally recognized express courier with proof of delivery, postage
prepaid and addressed to the Party to be notified at the address or addresses
indicated below, or upon the date of fax transmission of such notice (with proof
of such fax transmission established by the sender's fax receipt) using the fax
numbers listed below, or at such other address or fax number as such Party may
designate by ten (10) days' advance written notice to the other Party with
copies to be provided as follows:
IF TO ARENA, ADDRESSED TO:
Arena Pharmaceuticals, Inc.
0000 Xxxxx Xxxxx Xxxxx
Xxx Xxxxx, XX 00000 XXX
Attention: Xxxx Xxxx
President & CEO
Fax: (000) 000-0000
IF TO TAISHO, ADDRESSED TO:
Taisho Pharmaceutical Co., Ltd.
00-0, Xxxxxx 0-xxxxx,
Xxxxxxxxx
Xxxxx 000-0000, XXXXX
Attention: Xxxxxxx Xxxxxxxx
Group Manager, Business Development Group
Ethical Business Strategy Division,
Fax: 00-0000-0000
18.12 SURVIVING RIGHTS AND OBLIGATIONS. The following Articles and
Sections shall survive any termination or expiration of this Agreement: Article
I (Definitions); Article XI (Payment Arrangement); Article XII
(Confidentiality); Article XIII (Patent Infringement and Enforcement); Article
XIV (Representations and Warranties); Article XV (Indemnity); and Sections
5.3(d), 5.4, 18.8 and any payment otherwise subsequently or otherwise due under
Articles VII, VIII, IX and/or X. Upon expiration of Taisho royalty obligation
under this Agreement, all licenses and rights granted to Taisho hereunder shall
become fully paid-up irrecoverable license.
[Signature page on next page]
22
CONFIDENTIAL
WHEREUPON, the Parties have caused this Agreement to be executed by
their duly authorized agents, as of the dates listed below.
ARENA PHARMACEUTICALS, INC. TAISHO PHARMACEUTICAL CO., LTD.
By: /s/Xxxx Xxxx By: /s/Xxxxx Xxxxxx
----------------------------- ----------------------------
Name: Xxxx Xxxx Name: Xxxxx Xxxxxx
Title: President & CEO Title: President
Date: August 7, 2000 Date: September 18, 2000
23
CONFIDENTIAL
APPENDIX A
TAISHO SELECTED GPCRS
1. [*******************************], ALSO REFERRED TO AS "[*********]."
SELECTED BY TAISHO AS OF THE EFFECTIVE DATE.
24
CONFIDENTIAL
